Patrick Meehan, MD
Pulmonary Disease · Tacoma, WANPI 1740492040
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.6% of the total across 25 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 12 manufacturers, the largest accounting for just 14.6% — the pattern of someone who eats at a lot of different presentations.
Across 25 payments — averaging $43.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Fisher & Paykel Healthcare Inc$158
- Sentec, Inc.$151
- Abiomed$150
- Intuitive Surgical$125
- Vertex$109
- GSK$101
- plus $288 from 6 others
Across 38 payments — averaging $29,787 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Grifols Therapeutics LLC$449K
- GSK$411K
- Amgen$177K
- Boehringer Ingelheim$69K
- Pfizer$18K
- Boston Scientific$8K
What the payments were for
- Food & beverage$1,06699%
- Education$151%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Fisher & Paykel Healthcare Inc | 1 | $158 |
| Sentec, Inc. | 1 | $151 |
| Abiomed | 1 | $150 |
| Intuitive Surgical | 1 | $125 |
| Vertex | 1 | $109 |
| GSK | 6 | $101 |
| AbbVie(2 entities) | 4 | $84 |
| Sunovion Pharmaceuticals Inc. | 4 | $65 |
| Sanofi | 2 | $52 |
| Boehringer Ingelheim | 2 | $39 |
| Amgen | 1 | $29 |
| AstraZeneca | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FISHER & PAYKEL HEALTHCARE$790
- Impella$150
- Da Vinci Surgical System$125
- SYMDEKO$109
How this compares
$1,081 in reported general payments places this provider in the 65th percentile of 275 pulmonary disease providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrikaftaElexacaftor/Tezacaftor/Ivacaft | 13 | $349,928 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 165 | $157,922 |
| NucalaMepolizumab | 39 | $142,001 |
| XolairOmalizumab | 28 | $86,727 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 49 | $21,939 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 27 | $20,690 |
| SymbicortBudesonide/Formoterol Fumarate | 32 | $18,529 |
| Incruse ElliptaUmeclidinium Bromide | 28 | $17,578 |
| Spiriva RespimatTiotropium Bromide | 14 | $14,928 |
| Advair HfaFluticasone Propion/Salmeterol | 19 | $12,876 |
| Spiriva HandihalerTiotropium Bromide | 11 | $11,108 |
| Atrovent HfaIpratropium Bromide | 19 | $9,246 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $7,852 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 164 | $7,425 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 48 | $7,364 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Nucala, Anoro Ellipta, Incruse Ellipta, Breo Ellipta | $101 | $352,346312 claims |
| VertexTrikafta | $109 | $349,92813 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $19 | $39,21959 claims |
| Boehringer IngelheimSpiriva Respimat | $39 | $14,92814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 275 pulmonary disease providers in Washington.
Other pulmonary disease in Tacoma
- Jeffrey AlboresTacoma$8K
- Babith MankidyTacoma$6K
- Joseph Rey Dago-OcTacoma$5K
- Steven BennettTacoma$4K
- Rajesh KandasamyTacoma$4K
- Vincent MysliwiecTacoma$3K
- Jed GordenSeattle$236K
- Dominique PepperOlympia$212K
- Jiten PatelSpokane$200K
- Oneil BainsSeattle$156K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.